The new patent entitled, ‘Retinal Derivatives and Methods for the Use Thereof for the Treatment of Visual Disorders,’ covers methods of utilizing QLT091001 to treat diseases linked with an endogenous 11-cis-retinal deficiency.
QLT091001 is an experimental synthetic retinoid replacement for 11-cis-retinal, which is indicated for the treatment of Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
The US patent is owned by the University of Washington whrein QLT has an exclusive sub-license to the patent through its co-development agreement with Retinagenix.
The patent has a term expiring on 11 May 2027.
QLT president and CEO Bob Butchofsk said following the recent grant of orphan drug designations in the US for QLT091001 in the treatment of LCA and RP, the issuance of this patent brings additional value and protection to their synthetic retinoid program.